IBI363

· Innovent Biologics (Suzhou) Co. Ltd.

Drug timelines are a Plus or Pro feature.

17 regulatory and trial events tracked for IBI363, covering 2024-05-30 to 2026-04-27. Get the full timeline:

Most recent: Clinical Trial Update: IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed [Phase 3]

See pricing